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Decrease in quality of life predicts mortality in adult patients with 
pulmonary arterial hypertension due to congenital heart disease
I.M. Blok · A.C.M.J. van Riel · M.J. Schuuring · 
M.G. Duffels · J.C. Vis · A.P.J. van Dijk · 
E.S. Hoendermis · B.J.M. Mulder · B.J. Bouma
decreased or non-decreased QoL. Subsequently, the patients 
were followed for mortality.
Results Thirty-nine PAH-CHD patients (mean age 42, 44 % 
male, 49 % Down’s syndrome) were analysed. Following 
PAH-specific therapy, SF36 physical component summary 
(PCS) decreased in 13 (35–31 points, p = 0.001) and showed 
no decrease in 26 patients (34–43 points, mean values, 
p < 0.001). Post-initiation phase, median follow-up was 4.5 
years, during which 12 deaths occurred (31 %), 10 (56 %) 
in the decreased and 2 (10 %) in the non-decreased group 
(p = 0.002). Cox regression showed a decrease in SF36 PCS 
predicted mortality (HR 3.4, 95 % CI 1.03–11, p = 0.045).
Conclusions In PAH-CHD patients, decrease in SF36 PCS 
following initiation of PAH-specific therapy is a determi-
nant of mortality.
Keywords Congenital heart defect · Pulmonary arterial 
hypertension · Quality of life · Serial · Mortality
What is already known about this subject?
Patients with pulmonary arterial hypertension due to con-
genital heart disease (PAH-CHD) exhibit high morbidity 
and mortality. PAH-specific therapy has become the corner-
stone in the management of these patients due to beneficial 
effects on symptoms, haemodynamics and quality of life 
(QoL). In patients with left-sided heart failure a decrease in 
QoL is associated with higher mortality, but exercise train-
ing in these patients improves both QoL and mortality. It 
is currently unclear whether these findings are applicable 
to the PAH-CHD population, and whether QoL monitoring 
in these patients can identify those with a poor prognosis. 
Therefore, we investigated whether a decrease in QoL in 
adult PAH-CHD patients is associated with late mortality.
Abstract
Background Decrease in quality of life (QoL) in left-sided 
heart failure precedes poor survival, which can be reversed 
with exercise training. We investigated whether QoL is as-
sociated with mortality in pulmonary arterial hypertension 
due to congenital heart disease (PAH-CHD) patients.
Methods In this observational study, PAH-CHD adults re-
ferred for PAH-specific therapy were included. QoL surveys 
(SF36) were recorded during 2 years of therapy. Based on 
shift in SF36 scores during this period, patients had either 
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What does this study add?
Our study is the first to report that decrease in QoL is a pre-
dictor for late mortality in PAH-CHD.
How might this impact on clinical practice?
We recommend periodical assessment of QoL in PAH-CHD 
patients to facilitate early recognition of disease progression.
Introduction
Adults with congenital heart disease (CHD) have a lower 
life expectancy than their healthy counterparts [1], espe-
cially when pulmonary arterial hypertension (PAH) devel-
ops [2–7]. PAH-specific therapy has become the cornerstone 
in the management of these patients because of its beneficial 
effects on disease symptoms, haemodynamics and quality 
of life (QoL) [3, 8–10]. However, life expectancy and QoL 
still remain markedly impaired.
In patients with acquired heart failure, several studies 
found an association between baseline QoL and mortality 
[11, 12]. In addition, a decrease in QoL over time was signif-
icantly associated with increased mortality in these patients 
[13], suggesting QoL may identify patients in need for inter-
ventions to improve their survival. Furthermore, several 
studies in acquired heart failure revealed that survival and 
QoL can be improved by exercise training [14–16]. Thus, 
QoL has the potential to serve as both an important determi-
nant for mortality and a therapeutic target for treatment. The 
current study aims to investigate whether a decrease in QoL 
in adult PAH-CHD patients is associated with late mortality.
Methods
Study population
This was a prospective multicentre observational study of 
adult patients with PAH associated with CHD, including 
patients with Down’s syndrome [17, 18], referred for PAH-
specific therapy between January 2005 and May 2013. The 
current QoL study was part of an ongoing non-randomised 
trial on PAH-specific therapy in PAH-CHD patients [5]. 
Patients with all kinds of structural heart defects, including 
closed defects, could be enrolled. PAH was defined upon the 
echocardiographic PAH probability (tricuspid regurgitation 
velocity ≥ 2.9 m/s).
Study protocol
In the initiation phase of the study, PAH-specific therapy 
was started according to a standardised protocol [5]. This 
included the conduction of QoL questionnaires at stan-
dardised time intervals. After the initiation phase those QoL 
questionnaires were used to form individual QoL regression 
lines in order to divide patients into either a decreased or non-
decreased QoL group. Relevant improvement or decrease of 
QoL was defined as more than two points change during the 
initiation phase. Baseline (T0) was defined as the start of 
follow-up to determine survival, which was 2 years after the 
initiation phase in each patient.
According to the treatment protocol, patients were evalu-
ated with clinical examination, determination of functional 
class, 6-min walk distance (6-MWD), echocardiography, 
laboratory tests (including N-terminal pro-brain natriuretic 
peptide (NT-pro-BNP)) and quality of life questionnaires. 
These tests were all conducted 24, 21, 18, 15 and 12 months 
before T0 and at T0, apart from echocardiography which 
was performed twice a year.
Quality of life was evaluated using the 36-Item Short 
Form Health Survey (SF36), a well-documented, widely 
used and validated, self-administered QoL scoring system. 
It incorporated both a physical and mental component sum-
mary (PCS and MCS), thus reflecting physical and men-
tal health. The QoL questionnaires were filled out by the 
patient or, in case of Down’s syndrome, the patient’s parent 
or guardian. Survival and in case of death, time and causes 
of death during follow-up were obtained from the partici-
pating hospitals until March 2014. Doppler echocardiog-
raphy (VIVID 7 General Electric, USA) was performed to 
evaluate right ventricular function, using tricuspid annular 
plane systolic excursion (TAPSE) from M-mode recordings. 
Systolic pulmonary artery pressure was obtained from Dop-
pler recording using the modified Bernoulli equation.
Statistical analysis
Descriptive data were presented as mean ± SD if normally 
distributed or median with IQR, as appropriate. Categori-
cal data were evaluated using the chi-square statistic. The 
change of continuous variables was evaluated using a two-
tailed paired t test. Independent sample t test or Mann-Whit-
ney U test was used for comparison of continuous variables 
between two groups. Spearman’s analysis was used for 
correlation of numerous variables, as appropriate. Time to 
event analysis was performed with Kaplan-Meier estimates 
of survival. Log-rank test was performed to determine 
significant differences in mortality rate between the two 
groups. The associations between predictors and mortality 
were evaluated using univariate Cox regression analysis. 
All reported p values are two-sided, and values of p < 0.05 
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divided into two groups. Group 1 consisted of patients 
with decreased (Fig. 2b) and group 2 of patients with-
out decreased SF36 PCS regression lines (Fig. 2c). At T0 
mean SF36 PCS was 38 ± 12 (range 10.96–58.32, n = 39), 
which is more than one SD lower than the general popula-
tion. SF36 MCS was 49 ± 13 (22.96–66.79, n = 39), which 
closely resembles the mean score of the general population. 
The two groups, based on either decreased or non-decreased 
SF36 PCS, were well balanced with respect to most clinical 
characteristics. However, patients with decreased SF36 PCS 
had a lower baseline 6-MWD (p = 0.009) and New York 
Heart Association (NYHA) class (p = 0.006), compared 
with patients without a decrease. In contrast, no relation was 
found between change in SF36 PCS and change in 6-MWD 
(r = 0.12, p = 0.468).
The 39 patients who finished the initiation phase com-
pleted 131 questionnaires (median 4, range 2–5). In 13 
patents the SF36 PCS decreased by a mean of ten points 
(mean values 36–26, p = 0.006). In the 26 patients without a 
decrease, QoL improved in 20 patients (mean values 36–47, 
p = 0.006) and remained stable in 6 (mean values 31–33, 
p = 0.344). Decrease in SF36 PCS was equally distributed 
in patients with (53 %) and without (40 %) Down’s syn-
drome (p = 0.429). The effect size of decrease was similar 
in both groups (mean differences 5.3 and 5.1, respectively). 
Figure 3 shows the variability of the QoL scores during the 
initiation phase.
Mortality
During a median follow-up of 4.5 (range 0.3–6.4) years, 
total all-cause mortality was 31 % (12 deaths). Median 
time until death was 2.3 years. No patients died during the 
two-year initiation phase. Two (10 %) patients died in the 
non-decreased and ten (56 %) in the decreased QoL group 
(p = 0.002). Causes of death were right-sided heart fail-
ure (n = 7), sudden cardiac death (n = 2), sepsis (n = 1) and 
unknown (n = 2). Five-year mortality for all patients was 
18 %. Seven out of 19 patients with Down’s syndrome died 
during follow-up compared with 5 out of 20 non-Down 
patients (p = 0.423).
Using univariate Cox regression analysis, the significant 
determinants of mortality were age, NYHA classification, 
NT-pro-BNP, 6-MWD and decrease in SF36 PCS (Table 2). 
Patients with a decrease in SF36 PCS had a 5-year survival 
of 29 % compared with 74 % in those without a decrease in 
SF36 PCS (Fig. 4).
were considered significant. Statistical analysis was per-
formed with SPSS 20.0 (IBM Corp, Armonk, NY). Since 
this study focused on shift in QoL, only data from patients 
who returned more than one questionnaire were used in the 
final analysis.
Results
Patient cohort
Ninety-one adults (42 ± 14 year) with PAH-CHD were 
included (Fig. 1), divided over Amsterdam (64), Nijmegen 
(15) and Groningen (12). One patient refused treatment ini-
tiation. In five patients health insurance refused reimburse-
ment of treatment. In total 85 patients started standardised 
PAH-specific therapy (initiation phase). Of these, 61 (72 %) 
patients returned the first QoL questionnaire. Baseline char-
acteristics of these 61 patients are described in the supple-
mentary data (Table S1). In the 61 patients returning the first 
QoL questionnaire, no differences in QoL were found among 
those who continued and those who were lost to follow-up, 
for either the SF36 PCS (mean values 35–35 respectively, 
p = 0.930) or SF36 MCS (mean values 50–48 respectively, 
p = 0.426). In total 39 PAH-CHD patients (mean age 42 ± 12, 
44 % male, 49 % Down’s syndrome) completed the initia-
tion phase and their data were used for the final analysis.
Baseline characteristics at T0 are summarised in Table 1. 
Based on their individual SF36 PCS regression lines dur-
ing the two-year initiation phase (Fig. 2a), patients were 
Fig. 1 Flowchart of patient inclusion
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Our finding is in line with previous studies demonstrating 
an association between QoL and mortality, in healthy people 
[19] and in patients with acquired heart disease [11, 12, 20]. 
The above-mentioned studies used single instead of serial 
QoL measurements. In 2013, Apers et al. proposed that 
serial follow-up on QoL could be of more value than single 
measurements [21]. Four studies examined QoL with serial 
follow-up in CHD. They identified psychosocial determi-
nants of baseline and serial QoL [22, 23], analysed asso-
ciations between QoL and exercise capacity over time [24] 
Discussion
Quality of life and mortality
The current study shows, for the first time, that a decrease 
in QoL on the physical component of the SF36 during the 
initiation phase of PAH-specific therapy in adult PAH-CHD 
patients is associated with late mortality. Patients with a 
decrease in SF36 PCS had a 5-year survival of 29 % com-
pared with 74 % in those without a decrease in SF36 PCS. 
Table 1 Baseline characteristics at T0
Variables All patients Group 1 (decreased QoL) Group 2 (non-decreased QoL) p
Number 39 13 26
Age, mean ± SD (years) 42 ± 12 43 ± 10 42 ± 13 0.929
Male, n (%) 17 (44) 7 (54) 10 (39) 0.361
Down’s syndrome, n (%) 19 (49) 8 (62) 11 (42) 0.257
Eisenmenger’s syndrome, n (%) 35 (90) 13 (100) 22 (85) 0.135
Body mass index, mean ± SD (kg) 24 ± 4 25 ± 3 24 ± 4 0.731
NYHA class III or IV, n (%) 15 (43) 9 (75) 6 (26) 0.006
SF36 PCS, mean ± SD 38 ± 12 31 ± 11 41 ± 11 0.010
SF36 MCS, mean ± SD 49 ± 13 48 ± 13 50 ± 13 0.716
Medication
   Bosentan, n (%) 36 (92) 13 (100) 23 (89) 0.202
   Diuretics, n (%) 15 (39) 5 (39) 10 (39) 1.000
Cardiac surgery, n (%) 8 (23) 2 (17) 6 (26) 0.529
   Age surgery, median (range) (years) 6 (1–66) 5 (2–7) 8 (1–66) 0.643
Saturation in rest, mean ± SD (%) 85 ± 6 86 ± 6 85 ± 7 0.651
NT-pro-BNP, median (IQR) (ng/l) 429 (189–1197) 508 (270–1011) 382 (172–1263) 0.353
6-MWD, mean ± SD, (m) 385 ± 129 311 ± 112 422 ± 123 0.009
TAPSE, mean ± SD, mm 19 ± 6 19 ± 7 19 ± 5 0.785
SPAP, mean ± SD (mmHg) 93 ± 17 98 ± 17 90 ± 17 0.212
Shunt type
   Pre tricuspid, n (%) 6 (15) 2 (15) 4 (15)
   Post tricuspid, n (%) 18 (46) 5 (39) 13 (50) 0.760
   Complexa, n (%) 15 (39) 6 (46) 9 (35)
SF36 PCS short form health survey of physical health; SF36 MCS short form health survey of mental health; SD standard deviation; IQR 
interquartile range; QoL quality of life; 6-MWD six-minute walk distance; SPAP systolic pulmonary artery pressure; TAPSE tricuspid annular 
plane systolic excursion; NT-pro-BNP N-terminal pro-brain natriuretic peptide; NYHA functional class New York Heart Association functional 
class
aComplex shunts included atrioventricular septal defect and univentricular heart
Fig. 2 a Individual SF36 PCS regression lines of 39 PAH-CHD pa-
tients. b Decreased SF36 PCS regression lines, 13 patients. c Non-de-
creased SF36 PCS regression lines, 26 patients. All QoL measurements 
were recorded in the initiation phase after the start of PAH-specific 
standardised therapy. The thick lines represent the mean regression 
lines
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advanced disease. However, if decrease in QoL were merely 
a proxy for disease severity, one would expect baseline 
SF36 PCS to predict mortality as well and this was not the 
case. Given the results described above, we suggest the use 
of serial QoL follow-up in clinical practice to determine a 
patient’s mortality.
The relationship between decrease in QoL and late mor-
tality in adult PAH-CHD patients, as shown in our study, 
emphasises the importance of screening for decrease in 
QoL since periodical assessment could facilitate an early 
recognition of disease progression. A critical question is 
whether survival can be optimised in patients with disease 
progression. The use of knowledge from other areas of 
heart disease can be important for this task. In patients with 
and provided insight into the longitudinal course of QoL 
[25]. None of these studies evaluated mortality. We, how-
ever, demonstrate that assessing QoL with serial follow-up 
provides useful information about late mortality, suggest-
ing that serial follow-up may be a robust guide to clinical 
management in CHD patients. The use of patient-reported 
outcomes such as QoL instruments in clinical practice could 
help to screen for functional problems, to monitor disease 
progression or treatment effect, to stratify patients accord-
ing to mortality risk and to guide clinical management.
In order to implement serial QoL follow-up in clinical 
practice, its predictive value for mortality has to be weighed 
against traditional determinants of mortality in PAH-CHD. 
Unfortunately, multivariate regression analysis could not be 
performed in our study due to the small number of events. 
However, despite our number of events, decrease in QoL 
was significantly associated with mortality, making it a 
promising determinant.
It is possible that physical quality of life is a proxy for 
disease severity. In accordance, patients with decreased 
QoL on the physical component of the SF36 in our study 
had a lower 6-MWD and worse NYHA class implying more 
Fig. 3 Variability plot showing 
median, 25 and 75 % values of 
QoL scores during the initiation 
phase. a Variability of SF36 phys-
ical component summary scores. 
b Variability of SF36 mental 
component summary scores
 
Fig. 4 Kaplan-Meier survival curve between PAH-CHD patients with 
decreased and non-decreased SF36 PCS, 2 years after initiation of 
PAH-specific therapy
 Table 2 Determinants of survival at T0 in 39 PAH-CHD patients
Univariate analysis
HR 95 % CI p
Male gender 1.11 0.36–3.44 0.863
Age, per 5 years 1.29 1.06–1.56 0.009
Saturation at rest 1.02 0.94–1.12 0.594
Ferritin (µg/L) 0.99 0.97–1.02 0.613
NYHA 3 or 4 4.50 1.30–15.56 0.018
NT-pro-BNP, per 500 ng/L 1.15 1.04–1.27 0.005
6-MWD, per 10 m 0.92 0.87–0.97 0.003
SPAP (mmHg) 1.01 0.97–1.04 0.673
TAPSE (mm) 0.89 0.78–1.02 0.097
QoL PCS 0.98 0.91–1.05 0.534
QoL MCS 1.01 0.95–1.07 0.768
Decreasing saturation at rest 0.93 0.28–3.05 0.898
Decreasing NT-pro-BNP 0.91 0.27–3.04 0.874
Decreasing NYHA class 0.45 0.10–2.06 0.304
Decreasing 6-MWD 2.78 0.85–9.16 0.092
Decreasing SPAP 0.68 0.22–2.15 0.511
Decreasing TAPSE 2.82 0.75–10.64 0.126
Decreasing QoL PCS 3.38 1.03–11.12 0.045
Decreasing QoL MCS 1.61 0.43–5.95 0.478
HR hazard ratio; QoL quality of life; PCS physical summary score; 
MCS mental summary score; 6-MWD 6-min walk distance; SPAP 
systolic pulmonary artery pressure; TAPSE tricuspid annular 
plane systolic excursion; NYHA functional class New York Heart 
Association functional class; NT-pro-BNP N-terminal pro-brain 
natriuretic peptide
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CHD patients could facilitate early recognition of disease 
progression. Based on the association between QoL and 
mortality, it might be interesting for future studies in PAH-
CHD patients to evaluate whether interventions to improve 
QoL might influence survival.
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